After rallying from a loss in the morning session today as at January 08, 2018, ASX has reached to a month-long high. The Australian biotech market is expected to see growth to ~$25 billion which is currently valued at $23 billion. Australia is ranked in the top four in the world for their biotechnology capabilities, and they are the very best in the medical research area. Three biotechnology stocks that are doing well are as follows.
REVA MEDICAL, INC (ASX: RVA) – The geographic expansion of its commercial operations in seven European countries, as the company announces the addition of four new distribution partnerships. On the news of expansion, the stock price went up by 20% or $0.040 and traded at $0.240. As compared to nil or no revenue for the same period in 2017, during the six months ended June 30, 2018, REVA recognized $144,000 of net revenue. The stock has a low P/E of 0.240 and EPS of 0.819 AUD which compares well among the peer basket. By the end of September 30, 2018, the cash and the cash equivalent were $7,094 million. The market cap at current price is $83.01 million.
IMUGENE LIMITED (ASX: IMU) – The company appoints the president of the City of Hope National Medical Centre Professor Michael Caligiur in Los Angeles, to its Scientific Advisory Board. The elected president of the AACR in 2017 is the world’s largest cancer research organization. The company’s cash at the end of the period as September 30, 2018, stands at $23.83 million. From the Phase 1b study of its ‘HER-Vaxx gastric’ cancer vaccine in patients expressing the HER2 target protein, the company announces meeting study endpoints and positive top-line results. The stock has an EPS of -0.002 AUD and the market cap at current price is $68.59 million. The current price of the stock is $0.019.
VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT) – For Volpara and launch of the VolparaLive, the company recently reveals the successful RSNA 2018. Volpara Wins NZ Health IT International Solution of the Year Award while ScreenPoint medical and Volpara sign MOU. The recent research shows that quantitative analysis improves breast cancer screening. As such, in the HY the overall loss has risen to $5.0M. However, the company still retain $20M in the bank as at the end of Q2. An increase of 83% as compared to HY 2018, the revenue from customers are comfortably sitting at $2.3M. The stock price traded up by 12.5% at $1.260. The stock has an EPS of -0.057 AUD and the market cap at current price is $200.87 million.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.